Related Experiment Video
Updated: Apr 7, 2026

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
Decoding the secretase puzzle in amyloid-β generation: A state-of-the-art overview of the protease-mediated APP
Zuzanna Senkowska1, Ewelina Weglarz-Tomczak2
1Nature Innovation Laboratory (NatInLab), Amsterdam, the Netherlands.
Abstract:
The accumulation of amyloid β (Aβ) protein in the brain is a central pathological hallmark of Alzheimer's disease (AD). This process has become a major focus of interdisciplinary research and a critical target in drug development. Aβ is produced through the proteolytic processing of amyloid precursor protein (APP) by a group of enzymes known as secretases. They belong to different protease classes and operate through proteolytic cleavage of the peptide bond through several catalytic hydrolysis. Dysregulation of the expression or/and activity of proteases involved in APP processing disrupts the balance between the amyloidogenic and non-amyloidogenic pathways-often shifting it toward the amyloidogenic route. This shift leads to excessive production and further aggregation of Aβ peptides, ultimately resulting in neuronal toxicity. In this review, we integrate current state-of-the-art knowledge on all proteases reported to cleave APP, encompassing both canonical and non-canonical pathways, and offer detailed examination of cleavage-site topology, and catalytic mechanisms. By integrating the spatial and sequential hierarchy of APP proteolysis across cellular compartments, we establish a unifying mechanistic framework that captures the complexity of the process. We further delineate how distinct proteases-through defined active-site architectures, conserved catalytic motifs, and nucleophile-driven peptide bond hydrolysis-precisely regulate APP processing. This mechanistic perspective advances our molecular understanding of A pathogenesis and delineates critical catalytic control nodes amenable to therapeutic intervention. By defining these targets at a mechanistic level, it establishes a rational framework for precision drug design and the development of next-generation therapeutics.
More Related Videos
10:08Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
Published on: August 28, 2012
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Alzheimer's Disease: Treatment
Caspases